RT Journal Article
SR Electronic
T1 Unexpected Death of a Duchenne Muscular Dystrophy Patient in an N-of-1 Trial of rAAV9-delivered CRISPR-transactivator
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.16.23289881
DO 10.1101/2023.05.16.23289881
A1 Lek, Angela
A1 Wong, Brenda
A1 Keeler, Allison
A1 Blackwood, Meghan
A1 Ma, Kaiyue
A1 Huang, Shushu
A1 Sylvia, Katelyn
A1 Batista, Ana Rita
A1 Artinian, Rebecca
A1 Kokoski, Danielle
A1 Parajuli, Shestruma
A1 Putra, Juan
A1 Carreon, Chrystalle Katte
A1 Lidov, Hart
A1 Woodman, Keryn
A1 Pajusalu, Sander
A1 Spinazzola, Janelle M.
A1 Gallagher, Thomas
A1 LaRovere, Joan
A1 Baulderson, Diane
A1 Black, Lauren
A1 Sutton, Keith
A1 Horgan, Richard
A1 Lek, Monkol
A1 Flotte, Terence
YR 2023
UL http://medrxiv.org/content/early/2023/05/30/2023.05.16.23289881.abstract
AB An N-of-1 trial was developed to deliver a dCas9-VP64 transgene designed to upregulate the cortical dystrophin as a custom therapy for a Duchenne muscular dystrophy (DMD) patient. After showing signs of mild cardiac dysfunction and pericardial effusion, the patient acutely decompensated and sustained cardiac arrest six-days after dosing and succumbed two-days later. Post-mortem examination revealed severe acute-respiratory distress syndrome with diffuse alveolar damage. Vector biodistribution data was obtained and revealed minimal expression of transgene in liver. There was no evidence of AAV9 antibodies nor of effector T cell reactivity. These findings demonstrate innate immune signaling with capillary leak as a form of toxicity in an advanced DMD case treated with high-dose rAAV gene therapy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIND28497 NCT05514249Funding StatementThis study was funded by the 501c3 foundation Cure Rare Disease.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was reviewed and approved by the UMass Chan Medical School Institutional Review Board (IRB), Institutional Biosafety Committee, and Center for IRB Intelligence (CIRBI). External safety oversight was provided by an independent data safety monitor. The study was approved by the Food and Drug Administration (IND 28497). Families gave written informed consent for the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors